Immunotherapy for Infectious Diseases
Immunotherapy for Infectious Diseases Immunotherapy for Infectious Diseases
Principles of Vaccine Development 143 Fig. 4. Mechanism of activation of CD8 T-cells by chimeric viruses expressing T-cell epitopes. APC, antigen-presenting cell; CTL, cytotoxic T-lymphocyte; TCR, T-cell receptor. The immune response elicited by recombinant proteins follows the uptake by APCs and their processing in the endosomal compartment. Figure 5 illustrates the mechanisms of induction of immune response by recombinant protein expressing T-cell epitopes, which are contained in various bacterial organelles. Although the recombinant molecules are safe, they can induce strong responses against multiple antigenic determinants of carrier, and therefore the protective response might be diluted. Receptor-Mediated Delivery of Peptides The principle of this procedure is to artificially conjugate a peptide to a ligand interacting with a receptor or to a molecule expressed on the surface of APCs. Among the receptors able to internalize the conjugates are transferrin, ferritin, and �2-macroglobulin receptors The internalization of peptides can be achieved by conjugation of peptides with antibodies specific for a molecule expressed on APCs such as class I, class II, or Ig (20). The T-cells are activated subsequent to internalization of conjugates and their processing within APCs (Fig. 6). Until now this approach has had only academic interest because it is difficult to optimize coupling conditions as well as to preclude the formation of aggregates.
144 Bona Fig. 5. Mechanism of generation of peptides by proteins expressing foreign epitopes. Chimeric viruses are internalized within the cell subsequent to binding to cellular receptors. Subsequent to replication, viral proteins are produced and processed in endogenous pathways leading to the release of foreign peptide from the viral protein in which it was inserted. APC, antigen-presenting cell; TCR, T-cell receptor. Delivery of Peptides by Self Molecules Self protein molecules are an ideal tool to deliver peptides since they are safe and do not elicit immune responses against carrier protein. Three major approaches have been undertaken to construct such molecules: 1. Genetically engineered replacement of a segment of the VH gene (i.e., CDR3) with an oligonucleotide encoding a peptide recognized by T-cells. The resulting “antigenized” immunoglobulin molecules are taken up by APCs, which process chimeric Ig molecules and generate the peptide. 2. The peptide is attached to the sugar moiety of the Ig molecule by enzymatic engineering. This type of molecules can activate T-cells without the need for antigen processing since the molecule, by its Fc fragment, binds to the Fc receptor of APCs as well as to class II via the peptide attached to the sugar moiety (25). 3. Generation by genetic engineering of soluble class I or class II molecules in which the peptide is covalently linked to the heavy chain of class I or to the � chain of class II molecules respectively (26). Depending on the dose used, these molecules can stimulate or anergize the T-cells. Figure 7 illustrates the structure of such molecules. In the future new approaches will develop toward safe and efficient delivery of peptides using various self molecules.
- Page 103 and 104: 92 Kunert and Katinger 32. Lee S, e
- Page 105 and 106: 94 Kunert and Katinger 72. Abbs IC,
- Page 107 and 108: 96 Kunert and Katinger 117. Wright
- Page 110 and 111: From: Immunotherapy for Infectious
- Page 112 and 113: Dendritic Cells 101 several organis
- Page 114 and 115: Dendritic Cells 103 tion that infec
- Page 116 and 117: Dendritic Cells 105 chaperones such
- Page 118 and 119: Dendritic Cells 107 CD8� CTLs, th
- Page 120 and 121: Dendritic Cells 109 complete tumor
- Page 122 and 123: Dendritic Cells 111 19. Holland SM,
- Page 124 and 125: Dendritic Cells 113 mouse pneumonit
- Page 126 and 127: Dendritic Cells 115 dendritic cells
- Page 128 and 129: INTRODUCTION Cytokines, Cytokine An
- Page 130 and 131: Cytokines, Cytokine Antagonists, an
- Page 132 and 133: Cytokines, Cytokine Antagonists, an
- Page 134 and 135: Cytokines, Cytokine Antagonists, an
- Page 136 and 137: Cytokines, Cytokine Antagonists, an
- Page 138 and 139: Cytokines, Cytokine Antagonists, an
- Page 140 and 141: Principles of Vaccine Development F
- Page 142 and 143: Principles of Vaccine Development 1
- Page 144 and 145: Principles of Vaccine Development 1
- Page 146 and 147: Principles of Vaccine Development 1
- Page 148 and 149: Principles of Vaccine Development 1
- Page 150 and 151: Principles of Vaccine Development 1
- Page 152 and 153: Principles of Vaccine Development 1
- Page 156 and 157: Principles of Vaccine Development 1
- Page 158: Principles of Vaccine Development 1
- Page 162 and 163: INTRODUCTION Immunopathogenesis of
- Page 164 and 165: Immunopathogenesis of HIV Disease 1
- Page 166 and 167: Immunopathogenesis of HIV Disease 1
- Page 168 and 169: Immunopathogenesis of HIV Disease 1
- Page 170 and 171: Immunopathogenesis of HIV Disease 1
- Page 172: Immunopathogenesis of HIV Disease 1
- Page 175 and 176: 164 Connick counts ranged from 73 t
- Page 177 and 178: 166 Connick retinitis in an individ
- Page 179 and 180: 168 Connick A novel method of ident
- Page 181 and 182: 170 Connick occurs quite early in i
- Page 183 and 184: 172 Connick 2. Delta Coordinating C
- Page 185 and 186: 174 Connick 39. Hurni MA, Bohlen L,
- Page 187 and 188: 176 Connick 76. Dolan M.J., Clerici
- Page 189 and 190: 178 Connick 114. Komanduri KV, Visw
- Page 192 and 193: From: Immunotherapy for Infectious
- Page 194 and 195: Active Immunization for HIV Infecti
- Page 196 and 197: Active Immunization for HIV Infecti
- Page 198 and 199: Active Immunization for HIV Infecti
- Page 200 and 201: Active Immunization for HIV Infecti
- Page 202 and 203: Active Immunization for HIV Infecti
Principles of Vaccine Development 143<br />
Fig. 4. Mechanism of activation of CD8 T-cells by chimeric viruses expressing T-cell epitopes.<br />
APC, antigen-presenting cell; CTL, cytotoxic T-lymphocyte; TCR, T-cell receptor.<br />
The immune response elicited by recombinant proteins follows the uptake by APCs<br />
and their processing in the endosomal compartment. Figure 5 illustrates the mechanisms<br />
of induction of immune response by recombinant protein expressing T-cell epitopes,<br />
which are contained in various bacterial organelles.<br />
Although the recombinant molecules are safe, they can induce strong responses<br />
against multiple antigenic determinants of carrier, and there<strong>for</strong>e the protective response<br />
might be diluted.<br />
Receptor-Mediated Delivery of Peptides<br />
The principle of this procedure is to artificially conjugate a peptide to a ligand interacting<br />
with a receptor or to a molecule expressed on the surface of APCs. Among the<br />
receptors able to internalize the conjugates are transferrin, ferritin, and �2-macroglobulin receptors<br />
The internalization of peptides can be achieved by conjugation of peptides with antibodies<br />
specific <strong>for</strong> a molecule expressed on APCs such as class I, class II, or Ig (20).<br />
The T-cells are activated subsequent to internalization of conjugates and their processing<br />
within APCs (Fig. 6). Until now this approach has had only academic interest<br />
because it is difficult to optimize coupling conditions as well as to preclude the <strong>for</strong>mation<br />
of aggregates.